share_log

Reported Earlier, Moderna And Mitsubishi Tanabe Pharma Partner To Promote MRNA Respiratory Vaccine Portfolio In Japan

Benzinga ·  02:19

Under the agreement, Moderna will handle the manufacturing, sales, medical education and distribution of its mRNA respiratory vaccines. Both companies will engage in activities to enable broad access to Moderna's mRNA respiratory portfolio to have the maximum impact on public health in Japan. The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment